Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 2/20 | 0.71 |
| ▸ | ADCY1 | Q08828 | 11/20 | 0.57 |
| ▸ | ADCY8 | P40145 | 8/20 | 0.50 |
| ▸ | DCTPP1 | Q9H773 | 2/20 | 0.50 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23249435 | 0.91 | SLC2A1 (0.62) | SLC2A1ADCY1ADCY8SMN1; SMN2HTR2B | |
| SCHEMBL23249615 | 0.88 | SLC2A1 (0.77) | SLC2A1ADCY1ADCY8HTR2B | |
| SCHEMBL23249513 | 0.81 | SLC2A1 (0.67) | SLC2A1ADCY1ADCY8HTR2B | |
| SCHEMBL20673021 | 0.79 | SLC2A1 (0.81) | SLC2A1ADCY1ADCY8SMN1; SMN2HTR2B | |
| SCHEMBL23249629 | 0.78 | SLC2A1 (0.66) | SLC2A1ADCY1ADCY8HTR2BKDM4E | |
| SCHEMBL31591016 | 0.77 | KMT2A (0.58) | SLC2A1ADCY1ADCY8MAPTNPSR1 | |
| SCHEMBL31590900 | 0.76 | KCNJ6 (0.62) | SLC2A1ADCY1ADCY8SAE1KDM4E | |
| SCHEMBL20673018 | 0.76 | ADCY1 (0.71) | SLC2A1ADCY1ADCY8HTR2B | |
| SCHEMBL23249648 | 0.76 | ADCY1 (0.73) | SLC2A1ADCY1ADCY8HTR2B | |
| SCHEMBL31590936 | 0.75 | MAPT (0.56) | SLC2A1ADCY1ADCY8SMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-05-02 | — | — | US | disclosed |
| WO-2021077102-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021077102-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139190-A1 | NOVEL ANTIPARASITIC COMPOUNDS AND METHODS | TUBB, TUBB1, TUBA1C | SLC2A1 4433/4885ADCY1 4578/4885ADCY8 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.